X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CADILA HEALTHCARE - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CADILA HEALTHCARE SUN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 34.3 18.1 188.9% View Chart
P/BV x 2.7 4.1 64.6% View Chart
Dividend Yield % 0.5 1.0 47.7%  

Financials

 SUN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
CADILA HEALTHCARE
Mar-18
SUN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs701558 125.5%   
Low Rs433362 119.8%   
Sales per share (Unadj.) Rs110.4116.3 94.9%  
Earnings per share (Unadj.) Rs11.017.9 61.4%  
Cash flow per share (Unadj.) Rs17.223.1 74.5%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.40.8 46.3%  
Book value per share (Unadj.) Rs158.885.4 185.9%  
Shares outstanding (eoy) m2,399.261,023.74 234.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.0 129.9%   
Avg P/E ratio x51.625.7 200.7%  
P/CF ratio (eoy) x32.919.9 165.5%  
Price / Book Value ratio x3.65.4 66.3%  
Dividend payout %18.219.6 93.0%   
Avg Mkt Cap Rs m1,360,021470,664 289.0%   
No. of employees `00017.811.8 150.5%   
Total wages/salary Rs m53,67118,545 289.4%   
Avg. sales/employee Rs Th14,890.910,072.7 147.8%   
Avg. wages/employee Rs Th3,017.11,569.1 192.3%   
Avg. net profit/employee Rs Th1,480.61,547.7 95.7%   
INCOME DATA
Net Sales Rs m264,895119,049 222.5%  
Other income Rs m8,3881,132 741.0%   
Total revenues Rs m273,282120,181 227.4%   
Gross profit Rs m56,08128,475 196.9%  
Depreciation Rs m14,9985,388 278.4%   
Interest Rs m5,176911 568.1%   
Profit before tax Rs m44,29523,308 190.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4525,644 149.8%   
Profit after tax Rs m26,33818,292 144.0%  
Gross profit margin %21.223.9 88.5%  
Effective tax rate %19.124.2 78.8%   
Net profit margin %9.915.4 64.7%  
BALANCE SHEET DATA
Current assets Rs m316,35982,005 385.8%   
Current liabilities Rs m198,64360,720 327.1%   
Net working cap to sales %44.417.9 248.5%  
Current ratio x1.61.4 117.9%  
Inventory Days Days9573 129.6%  
Debtors Days Days10898 109.5%  
Net fixed assets Rs m213,17883,703 254.7%   
Share capital Rs m2,3991,024 234.3%   
"Free" reserves Rs m378,60686,421 438.1%   
Net worth Rs m381,00687,445 435.7%   
Long term debt Rs m17,72125,551 69.4%   
Total assets Rs m643,028180,653 355.9%  
Interest coverage x9.626.6 36.0%   
Debt to equity ratio x00.3 15.9%  
Sales to assets ratio x0.40.7 62.5%   
Return on assets %4.910.6 46.1%  
Return on equity %6.920.9 33.0%  
Return on capital %10.022.0 45.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81642,683 95.6%   
Fx outflow Rs m30,14311,242 268.1%   
Net fx Rs m10,67331,441 33.9%   
CASH FLOW
From Operations Rs m39,0729,193 425.0%  
From Investments Rs m-33,708-9,737 346.2%  
From Financial Activity Rs m-15,393515 -2,988.9%  
Net Cashflow Rs m-7,359-29 25,376.2%  

Share Holding

Indian Promoters % 63.7 74.8 85.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.3 61.8%  
FIIs % 23.0 5.9 389.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 11.0 75.5%  
Shareholders   133,026 44,069 301.9%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  ELDER PHARMA  ALEMBIC LTD  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 17, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS